Equities researchers at StockNews.com initiated coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.
Several other research firms have also recently commented on OTIC. Piper Sandler cut Otonomy from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $3.00 to $0.50 in a research note on Thursday, October 13th. HC Wainwright cut Otonomy from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 2nd.
Otonomy Stock Performance
NASDAQ:OTIC opened at $0.08 on Tuesday. Otonomy has a one year low of $0.07 and a one year high of $2.59. The business’s 50-day simple moving average is $0.18 and its 200 day simple moving average is $1.00. The stock has a market cap of $4.82 million, a price-to-earnings ratio of -0.11 and a beta of 1.19.
Institutional Trading of Otonomy
Otonomy Company Profile
Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.
- Get a free copy of the StockNews.com research report on Otonomy (OTIC)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Ardelyx is A Buy After Slip in Early 2022
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.